
Research News
-
Wet AMD Treatment Susvimo Preserves Vision for Five Years in Phase 3 Clinical Trial
Susvimo is an FDA-approved treatment that continuously delivers drug through a tiny, implanted capsule
-
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
The therapy delivers copies of the RORA gene to address multiple disease pathways.
-
Nanoscope Begins Rolling BLA Submission to FDA for Seeking Approval for its Optogenetic Therapy
The company plans to complete BLA submission in early 2026.
-
Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort
The expanded Phase 1/2/3 shortens time to potential FDA approval.
-
Retinitis Pigmentosa Research Advances
Recent developments in research on retinitis pigmentosa.
-
Stargardt Disease Research Advances
Recent developments in research on Stargardt disease.
-
Leber Congenital Amaurosis Research Advances
Recent developments in research on Leber congenital amaurosis.
-
Age-Related Macular Degeneration Research Advances
Recent developments in research on age-related macular degeneration.
-
In this in-depth interview hosted by InVivo, Jason Menzo, CEO of the Foundation Fighting Blindness, outlines the organization’s strategy for addressing significant changes and opportunities in the inherited retinal diseases (IRDs).